Welcome to the SpringWorks Therapeutics conference call. At this time, I will turn the call over to Samantha Sandler, Senior Director of Investor Relations. Thank you for joining us today for the OGSIVEO FDA approval call. Slides to accompany this conference call and audio webcast are posted in the Investors and Media section of our website at www.springworkstx.com. A replay of the audio webcast with the corresponding slides will also be available on the website following this call for a limited period of time. Leading the call today will be SpringWorks CEO, Saqib Islam. Before Saqib begins, I'd like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties, and that the company's actual results may differ materially from what is discussed during today's call. For a description of risk factors associated with investing in SpringWorks, please refer to our recent filing with the Securities and Exchange Commission. I will now turn the call over to Saqib. Thank you, Sam, and thank you for joining us to discuss the exciting milestone of the U.S. approval of OGSIVEO. I'm pleased to have Dr. Jim Cassidy, our Chief Medical Officer, Bhavesh Ashar, our Chief Commercial Officer, and Dr. Badreddin Edris, our Chief Operating Officer, here with me on today's call. The FDA approval of OGSIVEO is a watershed moment for the desmoid tumor community. After decades of waiting, patients now have an FDA-approved medicine that was developed specifically for them. I want to start by acknowledging that this approval is the culmination of good science, great clinical data, and a strong collaboration between the patient community, investigators, and industry, who have worked together to champion OGSIVEO's development path to approval. SpringWorks has been focused on the desmoid tumor community from the formation of our company, and we are privileged to deliver OGSIVEO to patients who are in tremendous need of an effective treatment. Desmoid tumors are pernicious and persistent tumors. As highlighted on slide six, their tendril-like growths can invade surrounding parts of the body and are difficult to control. Desmoid tumors can cause long-lasting pain, loss of physical function, and disfigurement. When vital structures are impacted, desmoid tumors can be life-threatening as well. We have heard time and again how the unpredictable nature and high likelihood of recurrence of these invasive tumors upends people's lives. In the absence of an FDA-approved therapy, physicians and patients have been forced to turn to various off-label treatment options, each of which has significant limitations. Systemic therapies such as chemotherapy and tyrosine kinase inhibitors show limited efficacy, can be slow to work, and carry with them undesirable side effect profiles. Surgery has been shown time and again to be a poor option for the majority of patients. The surgeries themselves are challenging due to the invasive nature of desmoid tumors. These procedures can be highly disfiguring and very often result in patients experiencing permanent pain thereafter. Sometimes to attempt to control desmoid tumors surgically, even amputations are required. In addition, desmoid tumors frequently grow back after surgery, oftentimes even more aggressive than the original tumors, leaving patients and physicians in a situation with even fewer good options. This was precisely the experience of DeAnn, who is pictured on this slide. Her desmoid tumor wrapped around her nerves, veins, and the artery behind her knee. She's had 10 surgeries, six to remove the tumors and four related to complications from the surgeries, and her tumor keeps growing back. She describes living in excruciating pain and has fought for years to save her leg from amputation. Our ambition is to change the outlook for these patients. Turning to slide seven. We believe that OGSIVEO can address the needs of desmoid tumor patients at any stage of their treatment journey. I'd like to take a moment to walk through our view of the patient population that we will serve, which can be organized into three groups. First, in the US, it is estimated that approximately 1,600 new patients are diagnosed annually with a desmoid tumor. Once diagnosed, time to initial active intervention can vary, but over the course of their disease, our market research indicates that over 90% of these patients will require treatment. Desmoid tumor experts and treatment guidelines now recommend systemic treatment as first-line intervention instead of surgery for most tumor locations. As the first and only approved therapy, OGSIVEO is well- positioned to be the new standard of care for desmoid tumor patients. A second group of patients includes those who were diagnosed in prior years but are still under active management. We estimate that there are approximately 6,000 such patients each year. This includes patients who've been continuously managed since the time of their initial diagnosis and those whose tumor may have returned after a period without treatment. We anticipate that OGSIVEO will be selected as the first or next systemic treatment option for these patients. Given that patients with desmoid tumors are typically first diagnosed in their twenties and thirties and therefore have to manage the disease over the course of their lifetimes, we estimate that there's a sizable total US diagnosed prevalent population of over 30,000 people. This is the third group, and while it includes patients who've experienced a resolution of their disease, it also includes many patients who continue to live with desmoid tumors and are not being actively treated for a variety of reasons, including the absence of a treatment option that meets their needs. We believe that a meaningful proportion of these individuals could benefit from OGSIVEO over time. We are energized by the opportunity for OGSIVEO to help many people with this devastating disease, regardless of where they are in their treatment journey. Moving now to slide eight. I'd like to highlight a few key points in the label that reflect the transformative benefits of OGSIVEO and our opportunity to serve a broad group of patients. First, OGSIVEO is approved for adults with progressing desmoid tumors who require systemic treatment. This indication will enable treatment of all adult patients whose desmoid tumor is progressing radiographically or symptomatically, which represents the clinical situations that drive systemic therapy use. In addition, the label contains no box warnings, no contraindications, and no REMS program. Second, the FDA-approved label includes strong efficacy data showing that treatment with OGSIVEO results in durable tumor shrinkage while also addressing pain. We are very pleased that the label specifically includes the favorable change from baseline in patient-reported worse pain. This is important given that pain is the most debilitating symptom reported by patients living with desmoid tumors, and reducing this burden is a key treatment goal for physicians. All of this speaks to the strength of our data, given how uncommon it is for patient-reported outcome measures that are secondary trial endpoints to be included in FDA labeling. Third, we believe that the safety and tolerability profile of OGSIVEO and our clinical trial data support the potential for extended duration of use. All in all, we believe that this broad label reflects the strength of our clinical data and the potential for OGSIVEO to be a practice-changing medicine and the new standard of care treatment for adult patients with desmoid tumors. I will now turn the call over to Jim Cassidy, who will discuss more details on the FDA-approved label, and then to Bhavesh Ashar, who will discuss our US plans for OGSIVEO. Jim? Thank you, Saqib. It's my pleasure to discuss the FDA-approved label in a bit more detail. Looking at slide 10, and as Saqib mentioned, OGSIVEO is approved for adult patients with progressing desmoid tumors who require systemic treatment. This indication enables treatment of all patients with desmoid tumor, is progressing radiographically or symptomatically, which are the clinical situations that drive physicians to prescribe a systemic therapy and are also fully consistent with the desmoid tumor treatment guidelines. Importantly, this indication has no limitations with respect to line of therapy. So in clinical practice, patients with desmoid tumors can be treated with OGSIVEO at any point of the disease journey. The recommended dosage is 150 mg orally, twice daily. The approval is based on our phase III DeFi trial, which was a rigorous, double-blind, placebo-controlled trial that enrolled a very advanced and difficult to treat desmoid tumor patient population. In DeFi, nirogacestat achieved statistically significant and clinically meaningful improvements across all the primary and all the key secondary endpoints, including pain, physical functioning, and overall quality of life. These results were published in The New England Journal of Medicine earlier this year and have been described as practice-changing by the physicians who take care of these patients. Here on slide 11 is a summary of the strong efficacy data from DeFi that is included in the U.S. prescribing information. Nirogacestat significantly improved progression-free survival, with a 71% reduction in the risk of disease progression. The confirmed objective response rate was 41% in the nirogacestat arm, versus a spontaneous regression rate of 8% for placebo. The complete response rate was 7%, with nirogacestat versus zero in the placebo arm. This is important because historically, patients with desmoid tumors have not achieved complete responses. The progression-free survival results were also supported by change from baseline and patient-reported worse pain in favor of the nirogacestat arm. This is especially noteworthy because while treatment goals for patients with desmoid tumors often focus on tumor growth points, such as progression-free survival, patients often present with severe and chronic pain. Pain reduction is a very important part of managing this disease. Given how uncommon it is for patient-reported outcome measures that are secondary trial endpoints to be included in FDA labeling, we believe this speaks to the strength of our data and the robustness of the clinical benefit demonstrated in the DeFi trial. Moving on to the safety summary on slide 12. As Saqib mentioned, the label does not include a box warning, a REMS program, or any contraindications... The warnings and precautions are consistent with our phase III trial data and are listed as diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancer, electrolyte abnormalities, and embryo- fetal toxicity. We've also listed on the slide the most common adverse reactions occurring in at least 15% of patients. Most of these side effects were managed with typical supportive care measures that practicing oncologists are very familiar with. All in all, we are delighted with the OGSIVEO label. We're all very excited to be able to deliver this first-ever approved therapy for desmoid tumor patients across the treatment journey, and to provide physicians with a systemic therapy that is uniquely well-suited for this disease. I'll now turn over the call to Bhavesh to discuss our US launch plans. Bhavesh? Thank you, Jim. It's a great privilege to deliver the first FDA-approved therapy for patients with desmoid tumors. As described earlier, these tumors are difficult to control and highly debilitating. OGSIVEO represents a significant advance for these patients, who have been suffering and waiting for years for an FDA-approved treatment. We are eager and ready to serve the desmoid tumor community, and I'm happy to share with you our plans to rapidly provide OGSIVEO to patients. Turning to slide 14, there is a solid foundation in place to support OGSIVEO becoming the standard of care for adults with desmoid tumors. An important underpinning in every successful launch is the opportunity to serve a community of patients who are in need of more effective treatments. We know that desmoid tumor patients prefer medication over surgery, but their needs have not been met with the off-label treatments that are currently available. Our market research and engagement with advocacy groups indicates that patients have been following the progress of our clinical development program, and there is a high awareness of OGSIVEO. These patients represent a community of strong advocates who are proactive in navigating their healthcare journeys, and we know that they are eagerly awaiting this new treatment. Importantly, we're also bringing a systemic therapy to this patient population at a time when both the thought leader community and treatment guidelines recommend systemic treatment as a first line of intervention for most tumor locations. In addition, new desmoid tumor-specific ICD-10 codes went into effect on October 1, which, as I will describe later, will boost our launch efforts. Next, we're bringing the first and only approved therapy to adult patients with desmoid tumors. As Jim described, OGSIVEO has demonstrated durable tumor shrinkage, positive improvements in quality of life, most notably meaningful reductions in pain, and a tolerability profile that has been shown in clinical trials to support extended duration of treatment. Lastly, awareness among physicians is high, and they are eager to make OGSIVEO available to their patients. Many desmoid tumor experts have firsthand experience with OGSIVEO, given that 90% of our phase III DeFi trial sites were sarcoma centers of excellence. Awareness has been further aided by the publication of the DeFi data in the New England Journal of Medicine this March. In addition, our market research with hundreds of oncologists has indicated high expected usage of OGSIVEO within the first year after approval, with approximately 90% of physicians indicating that they expect to prescribe our medicine. Importantly, more than 80% of physician respondents indicated that they plan to recontact patients who are not currently under active management upon the approval of OGSIVEO. Physicians are clearly motivated. Our commercial team has been working incredibly hard towards launch readiness in anticipation of this approval. We have a launch plan in place that centers around four strategic imperatives, which are shown here on slide 15. First, to drive adoption of OGSIVEO as the first or next systemic therapy. OGSIVEO is clearly differentiated based on its robust efficacy and its manageable safety profile. These attributes, coupled with being the only therapy with FDA approval, positions OGSIVEO to become the standard of care. A second imperative is to support patients through their OGSIVEO journey. We have created a comprehensive patient support program called SpringWorks Care Connections for patients who have been prescribed our therapy. I will share more details on this program later in the call. The third strategic imperative is to reinforce the leadership and commitment that SpringWorks has made to the desmoid tumor community over the last 6+ years. We have delivered on providing the first and only FDA-approved therapy for adult patients with desmoid tumors, and now have the privilege and responsibility to bring this important new medication to patients who need it. And fourth, we have the opportunity to expand the role of systemic therapy in treating desmoid tumors through physician and patient education. We continue to partner with thought leaders and advocacy groups to further increase the understanding of guideline-recommended patient management strategies, which favor systemic treatment as first-line intervention. This supports the opportunity for an FDA-approved therapy, like OGSIVEO, to be prescribed to a broader pool of desmoid tumor patients across their treatment journey. Moving to slide 16. As Saqib described earlier, while desmoid tumors are rare, patients are forced to live with and manage their disease over the course of their lifetime. There are approximately 1,600 newly diagnosed patients each year, many of whom will require immediate treatment, and about 6,000 patients who are currently under active management. Our goal is to help as many of these patients as we can and to do so as quickly as possible. We've assembled a seasoned team of top talent that is trained and ready for launch. This includes a US commercial field organization of 35 territory business managers, plus regional business directors, who have an average 20 years of rare disease and oncology experience. This team of 35 is further complemented by a group of nurse advocates and field access managers, as well as thought leader liaisons and payer account directors who will support their respective key stakeholders. Combined with a medical science liaison team who have been engaging with desmoid tumor experts for more than four years now, we have the right commercial and medical teams in place to effectively interact with healthcare providers, drive appropriate utilization of OGSIVEO, and support patients throughout their OGSIVEO journey. Turning now to our efforts to identify physicians who see patients with desmoid tumors, we found that there is a focus group of 1,500 physicians that treat a substantial portion of these patients. We'll focus here first to drive adoption of OGSIVEO amongst these physicians, who we know are actively treating patients today. Additionally, with the October launch of the desmoid tumor-specific ICD-10 codes, we will utilize available data sets to rapidly identify treating physicians who adopt these new codes. We expect adoption of these codes to grow over the next 12 months, further enhancing our ability to reach additional physicians. In addition, to drive steady growth over time, we will continue to educate on guideline-recommended treatment approaches and to generate awareness for OGSIVEO. These efforts will focus on community-based physicians who encounter patients with desmoid tumors less frequently, as well as those who still have a tendency to treat with surgery. With this approval, for the first time, there is an effective systemic treatment option available with clinical trial data that supports long-term use, which we believe will provide stronger rationale for these physicians to rethink how they treat desmoid tumors. All of this will be complemented by a continued investment in peer-to-peer, as well as other online educational efforts. Turning now to slide 17. We recognize that OGSIVEO can only bring value and change lives if it is accessible to patients who need it. We expect OGSIVEO to be available to order through our SpringWorks Specialty Pharmacy and Specialty Distributor network in the U.S. within the next five-10 business days. The wholesale acquisition cost for a 30-day supply of OGSIVEO is $29,000. As the first and only FDA-approved treatment for this rare and devastating disease, OGSIVEO is a highly innovative therapy for patients who are oftentimes in their prime years of life. OGSIVEO has demonstrated transformative clinical benefit to patients, including robust antitumor activity and reductions in pain. This brings significant value to patients, their families, physicians, and to the broader healthcare system. Our objective is that every appropriate desmoid tumor patient in the U.S. who can benefit from OGSIVEO will have access to our medicine. We are committed to ensuring that the desmoid tumor community is supported throughout their treatment journey, and we have been collaborating with patients, providers, and caregivers to understand their needs. These interactions have informed the design of a comprehensive and customized patient support program, called SpringWorks Care Connections, which is described on slide 18. With SpringWorks Care Connections, we will offer enrolled patients support throughout the insurance reimbursement process with financial assistance programs for eligible patients, including as little as a zero dollar copay, and programs for patients experiencing insurance delays or interruptions in coverage. We will also offer a patient assistance program that will provide OGSIVEO at no cost to eligible patients who do not have insurance or whose insurance is limited. Importantly, we expect that based on the average age of desmoid tumor patients, the majority will be covered by commercial insurance plans and hence eligible for $0 copay support. We have had discussions with health plans covering more than 98% of U.S. commercially covered lives and have received very positive feedback on the clinical profile of OGSIVEO and the significant benefits it provides to patients. We are truly honored to deliver OGSIVEO to patients with desmoid tumors who have been waiting for an approved and effective treatment. With a strong label in hand, we are eager and ready to launch. I'll now turn the call back over to Saqib. Thank you, Bhavesh. The SpringWorks team is eager to make a lasting, positive change in the lives of people with desmoid tumors.... As you've just heard, we are ready to serve patients in the United States, and we plan to file a marketing authorization application with the European Medicines Agency in the first half of 2024, to begin the process of bringing OGSIVEO to patients outside of the US. This is just the beginning for us. In addition to this first approval, we recently shared positive top-line data from our phase 2b ReNeu trial for mirdametinib, our MEK inhibitor, in children and adults with NF1-PN, which will support an NDA submission in the first half of 2024. This puts us in the unique position of potentially delivering two approved medicines to treat patients with two distinct devastating diseases over the next 18 months. We have 12 additional clinical development programs underway in a host of other devastating cancers. We look forward to providing transformative treatments to several patient groups in great need of new advances in the years ahead. In closing, we are incredibly proud of today's approval of OGSIVEO. We are grateful that this milestone positions us to execute on our ambition of changing the outlook for people with real need. We would like to thank the investigators who participated in our clinical trials, the patient organizations such as the Desmoid Tumor Research Foundation, who saw the promise of OGSIVEO, advocated for its continued development, and continue to be great partners, our employees for their relentless drive and dedication to our mission. Most of all, we'd like to thank the patients who participated in our clinical trials, and the families and loved ones that supported them along the way. Your courage and resilience in facing this devastating disease inspires all of us at SpringWorks. We will now open the line for questions. Operator? We'll now move the call to your questions. To ask a question, please press star one one. If your question has been answered and you'd like to remove yourself from the queue, please press star one one again. Please limit your questions to one each. Our first question comes from Anupam Rama with JP Morgan. Your line is open. Hey, guys! Thanks so much for taking the question, and congrats on the approval. Quick one for me. When you think about the language around progressing desmoid tumors in the label, based on your market research, in clinical practice, what portion of the time do physicians define progression by, say, a radiographic assessment versus a symptomatic assessment? Thanks so much. Well, we think. You know, first of all, thanks for the question, Anupam. Listen, we are delighted with the breadth of the label as we highlighted on the call, and we think that the label enables people living with desmoid tumors to who are newly diagnosed or currently managing their tumors, and covers them all as part of that label. Now, I think the benefit here is also extended to patients at any stage of their treatment journey. Up until now, as we think about the group of patients that are going to be covered by our label, as those with progressing tumors, the fact that we have pain in our label I think is a very important marker for the benefit that these patients will derive. When you think of our study, which had radiographic progression as the requirement for getting on to phase 3, that isn't the way that this is typically treated in the real-world setting. In the real-world setting, people come to their physicians with symptomatology like pain. So the fact that we are covering people with progressing tumors, defined either by symptomatology or radiographic progression, gives us both the confidence that we'll get the broadest group of patients covered and the confidence that physicians who want to prescribe OGSIVEO will be able to do so without hesitation or without any kind of time factor. So I think that demarcation between radiographic and symptomatology isn't one that's found in the real-world setting. It's really the symptomatology, and that we, that gives us a great deal of comfort in our ability to cover that broad group. Thank you. Our next question comes from Yaron Werber with Cowen. Your line is open. Great! Thanks for taking my questions, and congrats on this important day. I have a sort of an interrelated question, and I don't know how much you can answer it. Can you just remind us how many sites did you have in DeFi in the U.S.? And can you give us, you know, just remind us how many of those patients rolled into the OLE or sort of EAP, and maybe a little bit of a flavor, how many patients are on the EAP? Thank you. So, Jim, I will turn to you, and you can talk about the number of sites, and we'll go from there. So we had 30 sites in the U.S. that enrolled in the DeFi study. Many of these sites were sarcoma centers, but there were also patients who came from community physicians. I think, you know, at this point, Yaron, we aren't giving detail on the number of patients that rolled into either compassionate access or continuing use. We have a great deal of confidence, as we've talked about, in bringing the patients on the open label extension as well as compassionate use onto commercial a drug over, you know, over the coming months, but we haven't shared that data until now. But thank you for the question. Thank you. Our next question comes from Corinne Jenkins with Goldman Sachs. Your line is open. Yeah, thanks for the questions, and congrats this morning. Maybe a couple from us that are related. What portion of the actively treated patients that you referenced are currently on systemic therapies, and what is the rate of switching therapies within kind of a given year? And then I'd also be curious, of the 30 or so sites that were on the study, kind of what's the average number of patients those sites are seeing in a given year as well? So, Corinne, as it relates to let me take the second part of your question here. The 30, you know, we have not separated that out with respect to the data that we have at the moment. Can you repeat the first part of your question, Corinne? Because I had a tough time hearing you. How many patients are being seen at those sarc centers? So the question is, of what percentage of patients are being seen at the third sarc center? Go ahead, Bhavesh. So, our market research estimates that more than 40% of actively treated patients are seen at sarcoma centers and NCCN centers and academic centers. So there is a concentration of patients that are seen at these highly specialized institutions over their treatment journeys. I think to elaborate on that, Corinne, I would say that, you know, when we think of that 6,000 or so estimated patients that are under active management at the moment, you know, because of the fact that we've got this concentrated group of prescribers, Bhavesh referred to the 1,500 or so that we, you know, that we have identified. We have also used this period of time to identify a significant portion of the 6,000 of the 6,000 patients currently under treatment. So, I think that level of concentration and focus and awareness of OGSIVEO has allowed us to put ourselves in a good position to, particularly in a rare disease, to have a significant amount of patient identification already done. Thank you. Thank you. Our next question comes from David Nierengarten with Wedbush. Your line is open. Hey, thanks for taking my question. I was curious if you had any details on the physicians when you contacted them and said, and they said they would contact, you know, patients who maybe aren't actively being treated. You know, did they, did you go any deeper? Did you know, are those patients still suffering from pain, but there's no real treatment for them, so they're not actively treated or, you know, are they, you know, just relatively normal? They just know they, you know, they might have a recurrence at some time. Thanks. Yeah. So, thanks for the question, David. I think, again, we think about these as three distinct groups, right? So, 1,600 or so newly diagnosed patients per year, 6,000 patients who are currently being treated, right? So, you're not referring to either of those two groups in the question, you're referring to the third group, which is the 30,000 patients who have had a desmoid tumor, who are not getting a treatment right now. So what I can say, and I will turn to Bhavesh for more detail, is that a significant portion of those are people who have either already had a treatment, and are no longer dealing with symptoms, but a meaningful portion, we believe, do have symptoms and, by virtue of the fact that there was nothing that is working for them, are still in need of a treatment. Now, what gives us that confidence? We think of our phase 2 as well as our phase 3. We had people on a median of 4 prior lines of treatment before getting on nirogacestat for the clinical study. So we believe a significant portion, or a meaningful portion of that 30,000 are on the sidelines because there's nothing that works for them. Bhavesh, I'll turn to you for some more color. Yeah. So, just adding a bit more color to that response. We know that there, in that third group of physicians- of patients that Saqib referenced, there are patients in there who have previously tried the off-label therapies, et cetera, and have not tolerated them or have progressed on those therapies. There are patients that we hear from research also that have refused to take those currently available off-label treatments. And so with the availability of a new first and only FDA-approved option, physicians are telling us, right? So the data point from our research is that 80% of the physicians we surveyed indicated that they expect to recontact patients who basically today, not under active treatment or surveillance. The research also talks about these physicians estimate that 30% of the patients they've seen over the last 3 years are currently not receiving any active treatment. So all of those data points give us confidence as to the fact that there's patients in that larger group who will be appropriate, and physicians are motivated to call them for treatment. Thank you. Our next question comes from Alex with Barclays. Your line is open. Hey, good morning. This is Alex on for Peter. Congrats on the approval. Just a question on duration of therapy. Wondering if you could help us understand what your expectations are for average duration of therapy, you know, just based on the data and DeFi, as well as the longer-term data from your earlier studies, in desmoid patients. Thank you. Sure. Thanks, Alex. And so I'll start, and then I'll turn it over to Dr. Cassidy. You know, what we do know is the following, right? From you know, from our phase 1, from our phase 2, the median time on treatment was over 4 years. We do know from the phase 3, the median time on treatment was almost 2 years, but that is when we opened the blind and started analyzing the data. And we've got patients on open-label extension that extend beyond that. We believe that OGSIVEO will be and should be used for the chronic management of desmoid tumors. But for more detail, let me turn it over to Dr. Cassidy. Thanks, Saqib. So, we expect that patients will stay on therapy at the approved dose for as long as they are benefiting from the treatment. This is supported by the data in DeFi and data from our earlier studies in desmoid tumors, where patients were able to stay on the treatment at the recommended 150 milligrams twice daily dose for an extended period of time. Some patients in the trials have been on OGSIVEO for close to a decade. When you look back to our DeFi study, it's important to call out that patients that had required dose reductions due to side effects were specified in the protocol. Investigators tell us that in the real world, they would be more inclined to have early supportive measures in place to try to maintain that dose of 150 milligrams twice daily. Furthermore, the side effects that are seen with OGSIVEO are pretty common in oncology practice and are dealt with by physicians every day. So our feedback from physicians is that most of them are well-versed on how to manage these, and this does not produce an undue concern for the use of OGSIVEO. So all that said, OGSIVEO demonstrated strong antitumor activity and a manageable safety profile at the recommended 150 milligrams twice daily dose and schedule for an extended period of time. And we believe this will be important when physicians and patients are making treatment decisions. Thank you. Our next question comes from Alec Stranahan with Bank of America. Your line is open. Hey, guys. Thanks for the questions and want to offer my congrats on the approval as well. Could you speak to the competitive moat you expect to form as a first mover in DT? And how do you see Niro's differentiation versus other systemic therapies, either available now or in development, particularly against chemo, and other gamma secretases being developed for desmoid tumors? Thanks. No, just so thanks for the question, Alex. I mean, listen, I think, you know, from where we sit, we think the moat, as you describe it, I think is already relatively clear. The, the feedback we have from clinicians is that over 90% expect to use OGSIVEO as their next or their first systemic treatment choice, in dealing with desmoid tumors. And I think that the, the dissatisfaction stems from the challenges of the typical patient experience, right? So we said this before, but if 30 years ago, if you or I had a desmoid tumor, the first move would have been surgery. Well, now surgery is no longer recommended as first-line treatment for most patients because of an up to 70% recurrence rate. You see that in the patient experience, but we saw that in our studies where you had people with multiple surgeries. The next move would be chemo, TKIs, opioids. All of these are alternatives that people use that actually are false choices from our perspective. And there's a reason that nothing else is approved, because nothing else works over an extended period of time. That is what is driving the physician enthusiasm to indicate that over 90% of patients, they will push towards OGSIVEO, and they will go into their roster of patients who had not sought treatment because of the inadequacy of existing options and will recommend looking at OGSIVEO. We think the opportunity there is actually quite significant by virtue of the fact that not only we'll be the only approved systemic treatment, but we have the data supporting tumor size reduction, as well as, as well as symptomatology benefits across the board. Thank you. Thank you. This concludes today's call. Thank you for joining. You may now disconnect.